INFLAMASE Drug Patent Profile
✉ Email this page to a colleague
When do Inflamase patents expire, and what generic alternatives are available?
Inflamase is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in INFLAMASE is prednisolone sodium phosphate. There are eighty-eight drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Inflamase
A generic version of INFLAMASE was approved as prednisolone sodium phosphate by BAUSCH AND LOMB on July 29th, 1994.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for INFLAMASE?
- What are the global sales for INFLAMASE?
- What is Average Wholesale Price for INFLAMASE?
Summary for INFLAMASE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | INFLAMASE at DailyMed |
US Patents and Regulatory Information for INFLAMASE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | INFLAMASE FORTE | prednisolone sodium phosphate | SOLUTION/DROPS;OPHTHALMIC | 080751-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novartis | INFLAMASE MILD | prednisolone sodium phosphate | SOLUTION/DROPS;OPHTHALMIC | 080751-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
